Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cizzle Biotechnology HoldingsLSE:CIZ -2.63% EBITDA Margin % is 0.00% as of Dec. 2025. The stock has 4 warning signs investors should review. Among 941 Biotechnology companies, Cizzle Biotechnology Holdings ranks worse than 106269.82% on this metric.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Cizzle Biotechnology Holdings EBITDA Margin % Related Terms
Cizzle Biotechnology Holdings EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LSE:CIZ vs VRTX, REGN, RVMD: EBITDA Margin % Comparison
For the Biotechnology subindustry, Cizzle Biotechnology Holdings's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cizzle Biotechnology Holdings EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cizzle Biotechnology Holdings's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Cizzle Biotechnology Holdings's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cizzle Biotechnology Holdings (LSE:CIZ) has a EBITDA Margin % of 0.00% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Cizzle Biotechnology Holdings and its competitors. According to the industry distribution chart, Cizzle Biotechnology Holdings ranks #999999 out of 941 companies in the Biotechnology industry.
Is Cizzle Biotechnology Holdings' EBITDA Margin % too high?
Cizzle Biotechnology Holdings' current EBITDA Margin % is 0.00%. Based on the distribution chart, Cizzle Biotechnology Holdings ranks #999999 out of 941 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Cizzle Biotechnology Holdings' EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Cizzle Biotechnology Holdings ranks #999999 out of 941 companies for EBITDA Margin %. This places Cizzle Biotechnology Holdings in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Cizzle Biotechnology Holdings and its competitors. Cizzle Biotechnology Holdings's current EBITDA Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cizzle Biotechnology Holdings stock overvalued right now?
Cizzle Biotechnology Holdings (LSE:CIZ) has a current EBITDA Margin % of 0.00%. The current EBITDA Margin % is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Cizzle Biotechnology Holdings (LSE:CIZ), the current EBITDA Margin % is 0.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Cizzle Biotechnology Holdings PLC is a holding company of a group of companies (the Group) whose principal activity is the early detection of lung cancer via the development of an immunoassay test for the CIZ1B biomarker. Designed as a simple blood test, it enables early diagnosis before symptoms appear-when treatment options can transform outcomes for patients and families.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LSE:CIZ has been successfully added to your 
